TCON TRACON Pharmaceuticals, Inc.

-0.20  -7%
Previous Close 3.05
Open 2.95
Price To book 2.20
Market Cap 47.34M
Shares 16,609,000
Volume 80,341
Short Ratio 4.03
Av. Daily Volume 60,408

SEC filingsSee all SEC filings

  1. 8-K - Current report 17874123
  2. 424B3 - Prospectus [Rule 424(b)(3)] 17831738
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17831528
  4. 8-K - Current report 17830492
  5. D - Notice of Exempt Offering of Securities 17827865

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 dosing commenced May 24, 2017.
Prostate cancer
Phase 2 trial to be initiated 2H 2017.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 dosing initiated May 2016 with data due early 2018.
TRC105 and Nexavar
Hepatocellular carcinoma (HCC) - cancer
Phase 2 initiated Dec 2014. Phase 2 data top-line PFS data due 2H 2017.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 planned for 2016. Data due 4Q 2017.
Gestational Trophoblastic Neoplasia cancer
Phase 2 trial initiated January 2016.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2017.
Mesothelioma cancer
Phase 3 dosage of first patient announced February 16, 2017.
Angiosarcoma cancer
Phase 2 data due late 2016 according to 10Q filed November 2016. As of January 9, 2016, data have not been released and no mention of the trial was made in its January 9 presentation.
Soft tissue sarcomas

Latest News

  1. TRACON Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
  2. TRACON Doses First Patient in Phase 1/2 Study of TRC253 in Patients with Prostate Cancer
  3. TRACON Pharmaceuticals Announces Publication in Blood of Preclinical Data Indicating Activity of TRC105 in Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
  4. Edited Transcript of TCON earnings conference call or presentation 10-May-17 8:30pm GMT
  5. Tracon reports 1Q loss
  6. TRACON Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
  7. Investor Network: TRACON Pharmaceuticals, Inc. to Host Earnings Call
  8. TRACON to Report First Quarter Company Highlights and Financial Results on May 10, 2017
  9. TRACON Awarded ‘Most Innovative Trial Design’ for Phase 3 TAPPAS Clinical Trial of TRC105 in Angiosarcoma at 2017 Clinical and Research Excellence Awards
  10. TRACON Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
  11. TRACON Pharmaceuticals Announces TRC694 Data Presentation at Upcoming AACR Annual Meeting
  12. TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  13. TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
  14. TRACON Pharmaceuticals, Inc. :TCON-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  15. TRACON Pharmaceuticals to Present at the 29th Annual Roth Conference
  16. Edited Transcript of TCON earnings conference call or presentation 28-Feb-17 9:30pm GMT
  17. TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update